BGNE241115P100000
- 1.20
- 0.000.00%
BeiGene Newsroom
JMP Securities Maintains BeiGene(BGNE.US) With Buy Rating, Maintains Target Price $288
Decoding BeiGene Ltd (BGNE): A Strategic SWOT Insight
TD Cowen Maintains BeiGene(BGNE.US) With Buy Rating, Raises Target Price to $260
BeiGene Swings to Loss in Q3; Hong Kong Shares Slide 3%
[Hong Kong stock through train] Beigene (06160) fell 4.02% after performance, with Q3 turning from a year-on-year profit to a loss of 0.121 billion US dollars.
King's Wealth News | Beigene (06160) stock price under pressure, as of the deadline, dropped by 4.02%, closing at 116.9 Hong Kong dollars, with a turnover of 52.78 million Hong Kong dollars. On the news front, the company announced its third-quarter performance ending in September, with total revenue of 1.002 billion US dollars according to US Generally Accepted Accounting Principles, an increase of 28.2% year-on-year, mainly benefiting from the sales of Baiyuezhe in the USA and Europe increasing by 87% and 217% respectively. GAAP operating losses narrowed from 0.134 billion US dollars in the same period last year to 0.12 billion US dollars. During the quarter, an adjusted operating profit of 65.63 million US dollars was recorded, achieving non over two consecutive quarters.
BeiGene's Strong Performance and Promising Pipeline Drive Buy Rating
Beigene's total revenue in the third quarter was $1.002 billion, an increase of 28% year-on-year.
Beigene (06160) released the financial performance for the third quarter of 2024, with a net product revenue of 0.993 billion US dollars, an increase of 67% year-on-year; total revenue of 1.002 billion US dollars, an increase of 28% year-on-year; adjusted operational profit of 65.63 million US dollars.
beigene intends to use part of the proceeds from the over-allotment to permanently supplement working capital.
Beigene (06160) issued an announcement that the board of directors approved the proposal on November 12, 2024, regarding the permanent replenishment of working capital using part of the excess proceeds, agreeing that the company will use RMB 0.489 billion for permanent replenishment of working capital.
BeiGene Shares Are Trading Lower. The Company Reported Q3 Financial Results.
Express News | BeiGene Shares Are Trading Lower. The Company Reported Q3 Financial Results
10-Q: Quarterly report
Health Check: How Prudently Does BeiGene (NASDAQ:BGNE) Use Debt?
BeiGene Shenzhou Ltd. Third Quarter Report 2024
Asian Equities Traded in the US as American Depositary Receipts Down Sharply in Tuesday Trading
beigene's Q3 single-quarter revenue exceeded 1 billion US dollars. Will the two lawsuits with AbbVie affect future revenue?
①Beigene achieved product revenue of 7.079 billion yuan in the third quarter, with a total quarterly revenue of 7.139 billion yuan, and a revenue of 1.002 billion US dollars under the US GAAP, exceeding 1 billion US dollars in a single quarter for the first time. ②Excluding non-cash items such as share-based payment expenses, depreciation and amortization expenses, Beigene's adjusted operating profit for the third quarter was 65.63 million US dollars.
Beigene (688235.SH): Using 0.489 billion yuan of over-raised funds to permanently supplement working capital.
On November 12th, GeLongHui reported that Beigene (688235.SH) announced that the board of directors of the company approved the "Proposal on the Permanent Supplement of Working Capital using a portion of the excess funds" on November 12, 2024, agreeing that the company will use RMB 489 million of excess funds to permanently supplement working capital. The cumulative amount of excess funds used for permanent working capital within twelve months shall not exceed 30% of the total amount of excess funds, which will not affect the construction funding requirements of the fundraising investment projects. The company also commits not to engage in high-risk investments within twelve months after the capital supplementation.
Beigene (06160) achieved a single-quarter revenue of over 1 billion US dollars for the first time in Q3, and achieved non-GAAP operating profit for two consecutive quarters.
In the third quarter, Beigene continued its strong growth momentum, achieving revenue of 7.139 billion yuan, a year-on-year increase of 26.9%. Global product revenue reached 7.079 billion yuan, a year-on-year increase of 65.1%.
BeiGene Ltd. Unveils Q3 2024 Financial Highlights
Beigene (688235.SH) released its performance for the first three quarters, with revenue of 19.136 billion yuan, a year-on-year increase of 48.6%.
Beigene (688235.SH) released the third quarter report for 2024, with revenue for the first three quarters reaching...
beigene (06160.HK) achieved adjusted operating profit of 66 million US dollars in the third quarter. sales of Bavencio in europe increased significantly by 217%
Gelonghui November 12th | Beigene (06160.HK) announced that as of September 30, 2024, the company's total revenue reached 1.002 billion US dollars, compared to 0.781 billion US dollars in the same period in 2023, mainly benefited from the sales of Baiyuezhe in the USA and Europe, which increased by 87% and 217% respectively. In the third quarter of 2023, the company regained the global commercialization rights of Axitinib and Baizean, confirming the remaining deferred revenue of the previous Novartis collaboration project, contributing 0.183 billion US dollars to the total revenue of the same period last year. By the end of the third quarter of 2024, through adjustments.